Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer.
Ablation Techniques
/ methods
Adult
Disease-Free Survival
Dose-Response Relationship, Radiation
Humans
Iodine Radioisotopes
/ therapeutic use
Neoplasm Recurrence, Local
/ epidemiology
Patient Selection
Practice Guidelines as Topic
Radiation Oncology
/ methods
Radiotherapy Dosage
/ standards
Radiotherapy, Adjuvant
/ methods
Risk Assessment
/ standards
Thyroid Gland
/ pathology
Thyroid Neoplasms
/ mortality
Thyroidectomy
adjuvant treatment
differentiated thyroid cancer
iodine-131
patient selection
thyroid neoplasms
thyroidectomy
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 11 2020
01 11 2020
Historique:
received:
19
11
2019
revised:
14
03
2020
accepted:
09
04
2020
pubmed:
23
4
2020
medline:
20
4
2021
entrez:
23
4
2020
Statut:
ppublish
Résumé
Differentiated thyroid cancer (DTC) is the most common endocrine malignancy with a growing incidence worldwide. The initial conventional management is surgery, followed by consideration of
Substances chimiques
Iodine Radioisotopes
0
Iodine-131
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2345-2354Informations de copyright
© 2020 UICC.
Références
Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid. 2011;21:125-134.
Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375:1054-1067.
Konturek A, Barczynski M, Stopa M, Nowak W. Trends in prevalence of thyroid cancer over three decades: a retrospective cohort study of 17,526 surgical patients. World J Surg. 2016;40:538-544.
Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317:1338-1348.
Liu FC, Lin HT, Lin SF, Kuo CF, Chung TT, Yu HP. Nationwide cohort study on the epidemiology and survival outcomes of thyroid cancer. Oncotarget. 2017;8:78429-78451.
Kim DW, Choo HJ, Park JS, et al. Ultrasonography-guided fine-needle aspiration cytology for thyroid nodules: an emphasis on one-sampling and biopsy techniques. Diagn Cytopathol. 2012;40(Suppl 1):E48-E54.
Edino ST, Mohammed AZ, Ochicha O, Malami SA, Yakubu AA. Thyroid cancers in nodular goiters in Kano, Nigeria. Niger J Clin Pract. 2010;13:298-300.
Wiltshire JJ, Drake TM, Uttley L, Balasubramanian SP. Systematic review of trends in the incidence rates of Thyroid cancer. Thyroid. 2016;26:1541-1552.
Pereira MM, Williams VL, Hallanger-Johnson JE, Valderrabano P. Thyroid cancer incidence trends in the United States: association with changes in professional guidelines’ recommendations. Thyroid. 2020. https://doi.org/10.1089/thy.2019.0415.
Fahey FH, Grant FD, Thrall JH. Saul Hertz, MD, and the birth of radionuclide therapy. EJNMMI Phys. 2017;4:15.
Albano D, Bertagna F, Bonacina M, et al. Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines. Eur J Endocrinol. 2018;179:143-151.
Luster M, Aktolun C, Amendoeira I, et al. European perspective on the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Paper presented at: Proceedings of an Interactive International Symposium on Thyroid; 2018.
Verburg FA, Aktolun C, Chiti A, et al. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:1001-1005.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with Thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on Thyroid nodules and differentiated Thyroid cancer. Thyroid. 2016;26:1-133.
Tuttle RM, Ahuja S, Avram AM, et al. Controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid association. Thyroid. 2019;29:461-470.
Dizdarevic S, Tulchinsky M, McCready VR, et al. The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma. World J Nucl Med. 2019;18:123-126.
Avram AM, Fig LM, Frey KA, Gross MD, Wong KK. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? J Clin Endocrinol Metab. 2013;98:1163-1171.
Avram AM, Esfandiari NH, Wong KK. Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning. J Clin Endocrinol Metab. 2015;100:1895-1902.
Maruoka Y, Abe K, Baba S, et al. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma. Radiology. 2012;265:902-909.
Rosenthal MS, Angelos P, Bible K, et al. Informed consent for low-risk thyroid cancer. Int J Endocr Oncol. 2016;3:131-142.
Tulchinsky M, Baum RP, Bennet KG, et al. Well-founded recommendations for radioactive iodine treatment of differentiated thyroid cancer require balanced study of benefits and harms. J Clin Oncol. 2018;36:1887-1888.
Clement SC, Peeters RP, Ronckers CM, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma-a systematic review. Cancer Treat Rev. 2015;41:925-934.
Fard-Esfahani A, Emami-Ardekani A, Fallahi B, et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun. 2014;35:808-817.
Tulchinsky M, Binse I, Campenni A, et al. Radioactive iodine therapy for differentiated thyroid cancer: lessons from confronting controversial literature on risks for secondary malignancy. J Nucl Med. 2018;59:723-725.
Seo GH, Cho YY, Chung JH, Kim SW. Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: a Nationwide, population-based study in Korea. Thyroid. 2015;25:927-934.
Yu CY, Saeed O, Goldberg AS, et al. A systematic review and meta-analysis of subsequent malignant neoplasm risk after radioactive iodine treatment of thyroid cancer. Thyroid. 2018. https://doi.org/10.1089/thy.2018.0244.
Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. Basel, Switzerland: Springer International Publishing; 2018.
Momesso DP, Vaisman F, Yang SP, et al. Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine. J Clin Endocrinol Metab. 2016;101:2692-2700.
Park S, Kim WG, Song E, et al. Dynamic risk stratification for predicting recurrence in patients with differentiated thyroid cancer treated without radioactive iodine remnant ablation therapy. Thyroid. 2017;27:524-530.
Varma VM, Beierwaltes WH, Nofal MM, Nishiyama RH, Copp JE. Treatment of thyroid cancer. Death rates after surgery and after surgery followed by sodium iodide I-131. JAMA. 1970;214:1437-1442.
Leeper RD. The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab. 1973;36:1143-1152.
Cheng Q, Li X, Acharya CR, Hyslop T, Sosa JA. A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors. Oncotarget. 2017;8:16690-16703.
Shen X, Liu R, Xing M. A six-genotype genetic prognostic model for papillary thyroid cancer. Endocr Relat Cancer. 2017;24:41-52.
Qiu ZL, Wei WJ, Sun ZK, et al. Circulating tumor cells correlate with clinicopathological features and outcomes in differentiated thyroid cancer. Cell Physiol Biochem. 2018;48:718-730.
Avram AM, Dewaraja YK. Thyroid cancer radiotheragnostics: the case for activity adjusted (131)I therapy. Clin Transl Imaging. 2018;6:335-346.
Oltmann SC, Schneider DF, Leverson G, Sivashanmugam T, Chen H, Sippel RS. Radioactive iodine remnant uptake after completion thyroidectomy: not such a complete cancer operation. Ann Surg Oncol. 2014;21:1379-1383.
Schneider DF, Ojomo KA, Chen H, Sippel RS. Remnant uptake as a postoperative oncologic quality indicator. Thyroid. 2013;23:1269-1276.
Avram AM, Rosculet N, Esfandiari NH, et al. Differentiated Thyroid cancer outcomes after surgery and activity-adjusted 131I Theragnostics. Clin Nucl Med. 2019;44:11-20.
Bates MF, Lamas MR, Randle RW, et al. Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease? Surgery. 2018;163:118-123.
Carballo M, Quiros RM. To treat or not to treat: the role of adjuvant radioiodine therapy in thyroid cancer patients. J Oncol. 2012;2012:707156.
McMenemin RM, Hilditch TE, Dempsey MF, Reed NS. Thyroid stunning after (131)I diagnostic whole-body scanning. J Nucl Med. 2001;42:986-987.
McDougall IR. 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun. 1997;18:505-512.
Mourao GF, Rosario PW, Calsolari MR. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation. Endocr Relat Cancer. 2016;23:47-52.
Pacini F, Basolo F, Bellantone R, et al. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. J Endocrinol Invest. 2018;41:849-876.
Estorch M, Mitjavila M, Muros MA, Caballero E, en nombre del Grupo de Trabajo de Endocrinologia de la SEMNIM. Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature. Rev Esp Med Nucl Imagen Mol. 2019;38:195-203.
Ito Y, Miyauchi A, Oda H, et al. Appropriateness of the revised Japanese guidelines’ risk classification for the prognosis of papillary thyroid carcinoma: a retrospective analysis of 5,845 papillary thyroid carcinoma patients. Endocr J. 2019;66:127-134.
Heemstra KA, Liu YY, Stokkel M, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2007;66:58-64.
Lin JD, Huang MJ, Hsu BR, et al. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol. 2002;80:45-51.
Piccardo A, Arecco F, Puntoni M, et al. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival. Clin Nucl Med. 2013;38:18-24.
Ito Y, Kudo T, Kihara M, et al. Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors. Endocr J. 2012;59:119-125.
Carhill AA, Litofsky DR, Ross DS, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012. J Clin Endocrinol Metab. 2015;100:3270-3279.
Jonklaas J, Cooper DS, Ain KB, et al. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010;20:1423-1424.
Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229-1242.
Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879-885.
Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20:1235-1245.
Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:457-480. x.
Lamartina L, Durante C, Filetti S, Cooper DS. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab. 2015;100:1748-1761.
Verburg FA, Mader U, Reiners C, Hanscheid H. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. J Clin Endocrinol Metab. 2014;99:4487-4496.
Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 2018;7:44-51.
Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674-1685.
Schlumberger M, Leboulleux S, Catargi B, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol. 2018;6:618-626.
Tuttle RM. Distinguishing remnant ablation from adjuvant treatment in differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2019;7:7-8.
Sabra MM, Grewal RK, Ghossein RA, Tuttle RM. Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases. Thyroid. 2014;24:1088-1095.
Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab. 2015;100:1529-1536.
Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol. 2012;19:1874-1880.
Kazaure HS, Roman SA, Sosa JA. Insular thyroid cancer: a population-level analysis of patient characteristics and predictors of survival. Cancer. 2012;118:3260-3267.
Rosario PW, Xavier AC, Calsolari MR. Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients. Thyroid. 2010;20:1247-1252.
Pitoia F, Marlowe RJ, Abelleira E, et al. Radioiodine thyroid remnant ablation after recombinant human thyrotropin or thyroid hormone withdrawal in patients with high-risk differentiated thyroid cancer. J Thyroid Res. 2012;2012:481568.
Bartenstein P, Calabuig EC, Maini CL, et al. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. Thyroid. 2014;24:480-487.
Winter J, Winter M, Krohn T, et al. Patients with high-risk differentiated thyroid cancer have a lower I-131 ablation success rate than low-risk ones in spite of a high ablation activity. Clin Endocrinol (Oxf). 2016;85:926-931.
Gray KD, Bannani S, Caillard C, et al. High-dose radioactive iodine therapy is associated with decreased risk of recurrence in high-risk papillary thyroid cancer. Surgery. 2019;165:37-43.
Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A. Overall survival of papillary thyroid carcinoma patients: a single-institution Long-term follow-up of 5897 patients. World J Surg. 2018;42:615-622.
Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135:139-148.
Serrano-Nascimento C, Nicola JP, Teixeira Sda S, et al. Excess iodide downregulates Na(+)/I(−) symporter gene transcription through activation of PI3K/Akt pathway. Mol Cell Endocrinol. 2016;426:73-90.
Chung JH. Low iodine diet for preparation for radioactive iodine therapy in differentiated thyroid carcinoma in Korea. Endocrinol Metab. 2013;28:157-163.
Pluijmen MJ, Eustatia-Rutten C, Goslings BM, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2003;58:428-435.
Lee M, Lee YK, Jeon TJ, et al. Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas. Thyroid. 2014;24:1289-1296.
van Nostrand D, Khorjekar GR, O'Neil J, et al. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET. J Nucl Med. 2012;53:359-362.
Freudenberg LS, Jentzen W, Petrich T, et al. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging. 2010;37:2267-2276.
Juweid M, O'Dorisio T, Milhem M. Diagnosis of poorly differentiated thyroid cancer with radioiodine scanning after thyrotropin alfa stimulation. N Engl J Med. 2008;359:1295-1297.
van Velsen EFS, Stegenga MT, van Kemenade FJ, et al. Comparing the prognostic value of the eighth edition of the American joint committee on cancer/tumor node metastasis staging system between papillary and follicular thyroid cancer. Thyroid. 2018;28:976-981.